|Bid||88.73 x 1800|
|Ask||0.00 x 1200|
|Day's Range||88.69 - 91.24|
|52 Week Range||78.74 - 96.06|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.94|
|Expense Ratio (net)||0.13%|
It was a tough day for the market with all 11 sectors ending the day in the red. Health care, tech, and consumer discretionary were among the biggest losers of the day
Health care is on track for its worst quarter since March 2016. Should you buy the dip? With CNBC's Melissa Lee and the Fast Money traders, Carter Worth, Tim Seymour, Dan Nathan and Guy Adami.
A relentless bull says it's safe to buy tech again. With Wells Fargo's Scott Wren, CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Guy Adami.
Healthcare sector-related ETFs appeared sickly Friday as Johnson & Johnson (JNJ) dragged down the segment in response to reports that the company knew for decades that its baby powder contained asbestos. Healthcare stocks retreated after Reuters reported that the pharma giant knew for decades that the cancer-causing asbestos were found in its Baby Powder. In an examination of company memos, internal reports and other confidential documents, Reuters found that J&J known about the presence of trace amounts of asbestos in its products from as early as 1971.
Medtronic (MDT) reported net revenues of $7.5 billion in the second quarter of fiscal 2019 compared to $7.1 billion in the second quarter of fiscal 2018, reflecting 6% YoY growth.
The US jobs report for November was released today. The job additions came in at 155,000 as compared to consensus expectations of 198,000. While job additions in manufacturing remained strong at 27,000, construction net adds declined to 5,000.
In the last five years, AbbVie (NYSE:ABBV) stock is up 76%, which is impressive. Coming into today, AbbVie is down 5% in a year. The fundamentals, although very strong, are under attack from headlines about tariff wars especially between the United States and China.
The non-farm payrolls for October in the US (IVV) (QQQ) were 250,000 in October, which far outpaced economists’ consensus of 190,000. The strong job additions came after lackluster September additions of 134,000, which were further revised downward to 118,000 in October. After last month’s strong job additions, economists are expecting payrolls to come in at 200,000, which is below October’s payrolls but still healthy.
The outlook on GlaxoSmithKline PLC's credit rating was revised to negative from stable at Moody's Investors Service, which cited the drug giant's proposed acquisition of Tesaro Inc. . Moody's affirmed Glaxo's A2 long-term credit rating and its Prime-1 short-term rating. "We have changed [Glaxo's] outlook to negative as the company will deleverage more slowly than expected following the acquisition of Tesaro," said Moody's analyst Knut Slatten. "While the acquisition allows for a solid strengthening of [Glaxo's] oncology franchise, we expect credit metrics to remain weak for a prolonged period of time." Glaxo announced Monday an agreement to buy Tesaro in a cash deal valued at $5.1 billion, including debt. Glaxo's stock has gained 8.1% year to date through Tuesday, while the SPDR Health Care Select Sector ETF has rallied 12.8% and the S&P 500 has edged up 1.0%.
To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Friday’s open to this week’s Thursday close.